Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

N/A
2(100.0%)
2Total
N/A(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT06246227Active Not Recruiting

ctDNA for Early Detection of Recurrence in Melanoma

Role: collaborator

NCT07531121Active Not Recruiting

ctDNA for Risk Stratification in Melanoma

Role: collaborator

NCT07140445Not Yet Recruiting

Monitoring Neurocognitive Dysfunction and the Impact of Metabolism and Physical Capacity After Paediatric HSCT

Role: collaborator

NCT06373471Not ApplicableRecruiting

Improving Quality of Life in Older Patients With Frailty and Hematological Cancer Through Geriatric Assessment

Role: collaborator

NCT02385929Not ApplicableCompleted

Pre-habilitation of Patients With Head and Neck Cancer

Role: collaborator

NCT00639054Completed

The Molecular Characterization of Multiple Myeloma at Relapse

Role: collaborator

All 6 trials loaded